Nihon Kohden Reports January Status of Ongoing Share Buyback Program

An announcement from Nihon Kohden Corporation ( (JP:6849) ) is now available.

Nihon Kohden has reported the status of its ongoing share buyback program authorized by its board in December 2025, confirming that no shares were repurchased during the period from January 1 to January 31, 2026, despite approval to acquire common shares via ToSTNeT-3 and market purchases on the Tokyo Stock Exchange. Under the broader buyback authorization running through March 31, 2026, the company is permitted to purchase up to 3.8 million shares or ¥5 billion, and as of January 31 it has cumulatively acquired 718,200 shares for approximately ¥1.1 billion, indicating that significant capacity remains for further repurchases, which could affect capital allocation, share liquidity and shareholder returns over the remainder of the program.

The most recent analyst rating on (JP:6849) stock is a Buy with a Yen2015.00 price target. To see the full list of analyst forecasts on Nihon Kohden Corporation stock, see the JP:6849 Stock Forecast page.

More about Nihon Kohden Corporation

Nihon Kohden Corporation is a Japan-based medical device manufacturer listed on the Prime Market of the Tokyo Stock Exchange, specializing in patient monitoring systems, diagnostic equipment and other clinical technologies for hospitals and healthcare providers in domestic and international markets.

Average Trading Volume: 611,969

Technical Sentiment Signal: Buy

Current Market Cap: Yen286B

See more data about 6849 stock on TipRanks’ Stock Analysis page.